• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Amphetamines and Topiramate for Cocaine Use Disorder

Amphetamines and Topiramate for Cocaine Use Disorder

June 10, 2020
Rehan Aziz, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Rehan Aziz, MD. Dr Aziz has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Levin FR et al, Drug Alcohol Depend 2020;206:107700

In 2017, an estimated 2.2 million Americans used cocaine, with about 966,000 of them meeting criteria for cocaine use disorder (CUD) (SAMHSA, 2018). Unfortunately, there are still no FDA-approved treatments for CUD. Amphetamines increase synaptic dopamine transmission and may therefore reduce the reinforcing properties of cocaine. Topiramate, an anticonvulsant that enhances gamma amino butyric acid (GABA) activity, can reduce cocaine-induced dopamine release and may modulate the reinforcing effects of co-administered amphetamines. Previously, a single-site study suggested that a combination of amphetamine and topiramate can reduce cocaine use in individuals with high baseline cocaine consumption (Mariani JJ et al, Biol Psychiatry 2012;72(11):950–956). Now, researchers have conducted a larger trial with the same combination, among people who use cocaine, across two large metropolitan areas.

This trial tested the combination of mixed amphetamine salts extended-release (MAS-ER) and topiramate vs placebo in double-blinded, randomized design. The study was conducted over a 12-week period and included 127 adults (96 men, ages 18–60) with CUD. Participants reported using cocaine for at least 9 days in the previous month. MAS-ER was titrated to a maximum dose of 60 mg/day, and topiramate was increased to a maximum dose of 100 mg twice/day. The primary outcome was the proportion of individuals who achieved 3 consecutive weeks of abstinence, as measured by urine toxicology and self-report. Funding was provided by the National Institute on Drug Abuse.

The proportion of participants achieving 3 weeks of abstinence was significantly larger in the treatment compared to the placebo group (14.1% vs 0.0%, p = 0.03) after controlling for other factors. Secondary analyses showed that the proportion of participants who achieved any 3 consecutive weeks of abstinence (but not necessarily end-of-study abstinence) was higher for those receiving MAS-ER and topiramate (21.9%) compared to placebo (6.3%). Cocaine cravings also were significantly less prevalent among the treatment group (p < 0.001). Dropouts were high in both study arms (34% in the treatment group, 41% in the placebo group). Dry mouth was the only adverse event significantly more common in the treatment group than the placebo arm (16% vs 5%). Among those receiving MAS-ER and topiramate, 20.3% were discontinued from the medications due to increased blood pressure and heart rate.

CATR’s Take
The combination of amphetamine and topiramate can increase abstinence and decrease cravings among those with CUD. However, cardiovascular side effects limit widespread use, and it remains unclear whether the combination of MAS-ER and topiramate outperforms either medication alone.
Addiction Treatment
KEYWORDS cocaine pharmacology research research-update
    Rehan Aziz, MD.

    Medication Treatments for Alcohol and Opioid Use Disorder in Older Adults

    More from this author
    www.thecarlatreport.com
    Issue Date: June 10, 2020
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Emerging Risks for Old Medications, CATR, May/June 2020
    Gabapentin for Alcohol Use Disorder, Redux
    Does Baclofen Titrated to High Doses Reduce Alcohol Use?
    Amphetamines and Topiramate for Cocaine Use Disorder
    E-Cigarettes vs Nicotine Replacement for Smoking Cessation
    Benzodiazepines: Old Medicines, New Concerns
    Muscle Relaxants: Sedatives Often Under the Radar
    SAMHSA Relaxes Regulations on Methadone and Buprenorphine During COVID-19 Emergency
    Gabapentin Misuse and Diversion
    The “Z-Drugs”: Safety Issues and Misuse Potential
    Note From the Editor-in-Chief
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.